Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Recursion Pharmaceuticals

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement.

Benzinga

Jim Cramer Says This Financial Stock Is A 'Total Spec,' Likes Dutch Bros,

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Dutch Bros (NYSE: BROS). He recommended buying some now and then buying some of the stock in the $40s.

Benzinga

Looking for the Next Big Pop? Here’s Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce

While Recursion Pharmaceuticals has struggled for traction this year, the elevated short interest of RXRX stock and a key quant signal imply a near-term lift.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares are volatile on Tuesday following the release of the company’s second-quarter financial results. Here’s what you need to know.

Benzinga

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills

Imagine this: a hospital conference room, lights low, filled with decision-makers. A sales representative clicks through slides driven by Palantir Technologies’ (NASDAQ:PLTR) Foundry platform, highlighting real-time data integration and pinpoint analytics that would make Pharma RD from the past look like it’s still sending lab results by fax. Down the…

Benzinga

Top 2 Health Care Stocks You May Want To Dump This Quarter

As of July 22, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga

Why Is Recursion Pharma Stock Surging On Monday?

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood (vero_greenwood).

Benzinga

Read news from The Economist, FT, and more,
with one subscription

This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now?

Recursion Pharmaceuticals stock rallied as FDA announces plans of using AI for drug testing. Is it too late to invest in RXRX shares?

Barchart

Should You Buy These 2 Nvidia-Backed Stocks Now?

Is Nvidia’s investment a good reason to buy these stocks?

Barchart

Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market

Recursion Pharmaceuticals—a relatively small company backed by the chip giant Nvidia—is betting that its massive supercomputer will give it the edge to dominate the sector.

Fortune

2 Small-Cap Stocks Set to Skyrocket With Upside Potential Between 36% and 102%

These smaller stocks may carry more risk, but they also carry greater reward potential.

Barchart

Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?

Recursion Pharmaceuticals' stock has soared due to Nvidia's continued investment, positioning the company as a leader in AI-driven drug discovery.

MarketBeat

Biotechs on the Brink: 2 Stocks With Huge Potential

BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.

MarketBeat

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

1 AI Biotech Stock That Just Scored a Major Milestone

Down over 85% from all-time highs, Recursion Pharmaceuticals is an AI-powered biotech company that aims to accelerate the drug discovery process.

Barchart

AI Could Power Up These 2 Biotech Stocks

AI is rapidly transforming the healthcare industry. Evolving companies such as Intuitive Surgical and Recursion Pharmaceuticals can capitalize on this opportunity.

Barchart

Should You Buy the Dip in This AI-Driven Drug Stock?

Down 76% from all-time highs, is this AI-powered drug stock a good buy right now?

Barchart

3 Small-Cap Stocks Set To Skyrocket

These under-the-radar companies may offer greater long-term rewards.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

6 Under-the-Radar AI Stocks That Analysts Expect to Rally

Morgan Stanley is betting on these stocks to benefit from the AI megatrend.

Barchart

1 AI Growth Stock With 54% Upside Potential

Shares of Recursion Pharmaceuticals offer solid upside potential, given the company's trailblazing approach to drug discovery leveraging AI. Here’s a closer look at the biotech stock that has garnered investments from both AI chipmaker Nvidia and ARKK fund manager Cathie Wood.

Barchart

Nvidia Just Invested $76 Million in 1 Cathie Wood Stock

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

Barchart

Nvidia Just Invested $76 Billion in 1 Cathie Wood Stock

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

Barchart

1 Cathie Wood Stock With Over 100% Upside, According to Analysts

This biotech stock under $10 is the newest addition to Cathie Wood's flagship ARKK fund - and Wall Street analysts have high hopes for the shares, too.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022

Benzinga

Recursion Pharmaceuticals's Return On Capital Employed Insights

Recursion Pharmaceuticals (NASDAQ:RXRX) brought in sales totaling $2.53 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 36.91%, resulting in a loss of $64.93 million.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.